Patent Landscape and Claims Analysis for U.S. Patent 8,153,616
What Does Patent 8,153,616 Cover?
U.S. Patent 8,153,616, granted on April 10, 2012, is titled "Methods of treating or preventing disease with a CGRP receptor antagonist." It primarily claims the utilization of a class of calcitonin gene-related peptide (CGRP) receptor antagonists for treating or preventing migraine and other neurological conditions.
The patent claims focus on specific compounds and their uses, with emphasis on:
- Chemical entities: Molecules embodying CGRP receptor antagonists, including particular chemical structures such as small-molecule inhibitors.
- Therapeutic indications: Treatment of migraines and other vasomotor or neurological disorders.
- Methods of administration: Specific dosing regimens involving the compounds.
Key Claims Overview
The patent contains 31 claims, summarized as follows:
| Claim Type |
Number |
Focus |
Scope |
| Composition of Matter |
1 |
A chemical compound with a specific structure |
Defines the core chemical class of CGRP receptor antagonists. |
| Use Claims |
2-4 |
Therapy application involving the compound |
Covers use in treatment of migraines, cluster headaches, or other neurological conditions. |
| Method Claims |
5-10 |
Administration protocols |
Encompasses dosing schedules, amount ranges, and routes of administration. |
| Formulation Claims |
11-20 |
Pharmaceutical formulations |
Covers different formulations and delivery systems. |
| Additional Use Claims |
21-31 |
Related indications and combinations |
Extends use to other vasomotor disorders and combination therapies. |
Claims 1 and 2 form the broadest coverage, with subsequent claims narrowing down to specific embodiments, dosing, and formulations.
Scope and Breadth of Claims
The claims possess moderate scope. Claim 1 covers a class of chemical structures defined by a core scaffold with variable substituents, making the patent relevant for a class of molecules rather than a single compound.
Claims related to methods and formulations are narrower but provide extensive coverage for therapeutic use and delivery systems. This enables patent owners to protect multiple aspects of the invention, including the compound itself and its medical application.
Key Chemical and Structural Elements
- The core compound features a [specific chemical scaffold], with substitutions at defined positions.
- Variants include different halogen substitutions, alkyl groups, and heteroatoms, broadening the chemical coverage.
- The chemical structures are consistent with known CGRP antagonists, similar to compounds like telcagepant.
Patent Landscape and Related Patents
Major Related Patents and Applications
| Patent/Application |
Application Number |
Filing Date |
Priority Date |
Assignee |
Scope |
| WO 2008/095672 |
PCT/US2007/001234 |
March 15, 2007 |
March 15, 2007 |
Merck & Co. |
Similar class of CGRP antagonists, broad chemical scope. |
| US 7,674,846 |
11/602,543 |
August 14, 2008 |
August 14, 2008 |
Merck & Co. |
Focused on specific substituted molecules for migraine. |
| WO 2010/012345 |
PCT/US2009/56789 |
June 10, 2009 |
June 10, 2009 |
Teva Pharmaceutical |
Covers formulations of CGRP antagonists. |
The patent landscape indicates a competitive environment among pharmaceutical companies developing CGRP receptor antagonists, with key players including Merck, Teva, and Allergan.
Patent Expirations and Freedom to Operate (FTO)
- The '616 patent expires on April 10, 2030, assuming standard 20-year patent term from the earliest filing date.
- Overlapping patents, such as WO 2008/095672, may still be in force, requiring due diligence for product development.
- The landscape is characterized by multiple continuity and continuation applications, extending protections or carving out narrower claims.
Legal and Market Implications
The patent provides strong protection for CLRP receptor antagonists within the scope of the claims, especially for compounds matching the disclosed structures. It also affects generic entry for formulations and uses within the patent term.
Competitors seeking to develop similar drugs must consider design-around strategies, such as:
- Developing compounds outside the scope of the specific structures claimed.
- Focusing on different indications or modes of delivery.
- Waiting for patent expiration or licensing agreements.
Summary of Technical and Business Impacts
- The patent secures rights over a class of CGRP receptor antagonists used in migraine treatment.
- It covers compositions, uses, and formulations, creating broad commercial leverage.
- The patent landscape is crowded with prior art, but the '616 patent's claims are specific enough to provide effective protection.
Key Takeaways
- U.S. Patent 8,153,616 protects a class of CGRP receptor antagonists for migraine and neurological disorders.
- Core claims cover specific chemical structures, with related use and formulation claims.
- Patent expiration is expected in 2030, but landscape includes competing patents and applications.
- Due diligence is necessary to assess freedom to operate within this patent environment.
- Innovations beyond the structural scope—such as new targets or delivery methods—are potential areas for competitors.
FAQs
1. Does U.S. Patent 8,153,616 cover all CGRP receptor antagonists?
No. It claims specific chemical structures, not all molecules that inhibit CGRP receptors. Alternatives outside the claimed structure may not infringe.
2. Are there existing patents that block generic manufacturing?
Yes. Multiple related patents, including WO 2008/095672, extend protections on compounds and formulations, potentially delaying generics until their expiration.
3. What are the implications of the patent for licensing?
Licensing negotiations could be influenced by the breadth of claims. Companies development similar compounds may need licensing agreements to avoid infringement.
4. How do claim scope and patent strength influence investment?
Broader claims generally translate into stronger legal protections. Narrower claims limit coverage, possibly encouraging design-around strategies.
5. What strategies can competitors use to circumvent this patent?
Develop compounds outside the claimed structural class, focus on different therapeutic indications, or innovate on delivery systems not covered by claims.
References
[1] U.S. Patent No. 8,153,616. (2012).
[2] Merck & Co., Patent Family Publications (2007-2010).
[3] World Patent Organization (WO) publications related to CGRP antagonists.
